767340-03-4, name is (2Z)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-yl]-1-(2,4,5-trifluorophenyl)but-2-en-2-amine, belongs to pyrazines compound, is considered to be a conventional heterocyclic compound, which is widely used in drug synthesis. The chemical synthesis route is as follows. name: (2Z)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-yl]-1-(2,4,5-trifluorophenyl)but-2-en-2-amine
To 30 ml of degassed triflouroethanol (TFE) were added Ruthenium(II) chloride 1,5-cyclooctadiene complex (18.2 mg, 0.037 mmol) and (R )-(-)-H(S)-2- Diphenylphosphino)ferrocenyl]ethyl di-tert-butylphosphine (44.8 mg, 0.083 mmol). The solution was degassed again, and left to stir at room temperature for 1 hour. To 250 ml glass reactor were added (Z)-3-amino-l-(3-(trifluoromethyl)-5,6-dihydro- [l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)but-2-en-l-one (30 g, 74.07 mmol) and 100 ml TFE. The slurry was stirred and washed three times with N2. Than, the catalyst solution was added and the mixture washed three times with N2, then switched to H2 and washed three times. The H2 pressure was set to constant pressure of 5 bar and the reaction was heated to 55C for 23 hours. The TFE solution (93.3% purity and 77% R) was evaporated to yield oily-STG-base.
The synthetic route of 767340-03-4 has been constantly updated, and we look forward to future research findings.
Reference:
Patent; TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.; WO2009/70314; (2009); A2;,
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem